WHO Drafting Regulatory Convergence White Paper On Cell And Gene Therapies, US FDA's Marks Says
Executive Summary
Regulators in high-income countries have a responsibility to help health authorities in low- and medium- income countries develop regulatory frameworks for cell and gene therapy products to ensure these treatments are available to all, asserts the US FDA’s biologics center’s director.
You may also be interested in...
Gene Therapy Manufacturing Hurdle: Sponsors Unwilling To Share ‘Secret Sauce’
US FDA’s Peter Marks says companies are not exchanging information about adenoviral factors, which is probably slowing down the field. He describes NIH's plans for a bespoke gene therapy consortium for vector generation and continued efforts for regulatory harmonization.
US FDA's Marks: Gene Therapy Success Could Hinge On Regulatory Convergence
Biologics center's director encourages sponsors to invite other regulators to early FDA meetings in effort to scale up markets.
World Regulators Wrestle With Advanced Therapies
The development of advanced therapy medicinal products is dogged by a lack of regulation and guidance and differences in what should and should not be deemed an ATMP, according to speakers at last month’s pre-ICDRA gathering of world regulators.